Clinical Microbiomics A/S, a leading innovator in bioinformatics and systems biology for the microbiome field based in Copenhagen, Denmark, announces the merger with CosmosID Inc, a leading CLIA-certified, GxP-compliant microbiome CRO based in Germantown, Maryland, United States.
The gut microbiome has clear implications for health and disease. Recent evidence of this comes from a US FDA vote for approval of the microbiome-based drug RBX2660, created by Rebiotix Inc, A Ferring Company, to treat potentially deadly bacterial infections with Clostridium difficile (Cdiff). Cdiff is a common gut bacteria that may cause severe diarrhea...
A recent article in the Washington Post highlights a link between the gut microbiome composition and cancer immunotherapy treatment outcomes. The human gut microbiome consists of a vast array of bacteria, fungi, phages and other microbes. The interactions between the microbes and their interconnection with the host affects host immunity, health and homeostasis. In this...
Collaboratively administrate empowered markets via plug-and-play networks. Dynamically procrastinate B2C users after installed base benefits. Dramatically visualize customer directed convergence without revolutionary ROI. Proactively envisioned multimedia based expertise and cross-media.
Source CosmosID, a leader in the field of microbiome analysis, announced today the launch of both long-read and hybrid sequencing offerings for comprehensive genome assembly and analysis. By utilizing both Oxford Nanopore Technologies (ONT) and Illumina based sequencing, CosmosID has developed optimized bioinformatic solutions for greater genome assembly capabilities, resulting in decreased number of...
© 2023 CosmosID. All rights reserved